Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.

Aging - 2 Aug 2023

An Fengxiao, Zhang Wenjing, Guo Yuxian, Shi Fuyan, Kong Yujia, Tang Liguo, Han Caijing, Wang Qinghua

Abstract excerpt

SET binding protein 1 (SETBP1) plays crucial roles in various biological processes; however, its involvement in cancer immune checkpoint inhibitor (ICI) treatments has never been studied. In this study, we collected a total of 631 melanoma and 109 non-small cell lung cancer (NSCLC) samples treated with ICI agents (i.e., anti-CTLA-4, anti-PD-1/PD-L1, or combination therapy). Additionally, we obtained their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Carrier Proteins

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Melanoma

Share to Nuclear Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 37535001
DOI: 10.18632/aging.204913
PMCID: PMC10457048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.PMID 37535001Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanomaSemantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.Semantic proximity Read ↗

Mutated Processes Predict Immune Checkpoint Inhibitor Therapy Benefit in Metastatic MelanomaSemantic proximity Read ↗

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.